ARMK — Aramark

Summary of Aramark (ARMK) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Organic Revenue: Increased by 14%, driven by new business and base growth.
• Full Year Revenue: GAAP revenue of $18.5 billion, up 6% year-over-year; organic revenue growth of 7%.
• Adjusted Operating Income (AOI): Q4 AOI was $289 million, up 6% (constant currency), with full-year AOI at $981 million, a 12% increase (constant currency).
• Adjusted EPS: Q4 adjusted EPS of $0.57 (up 6%), with full-year adjusted EPS of $1.82 (up nearly 20%).
• Leverage Ratio: Improved to 3.25x, the lowest in nearly 20 years.
• Free Cash Flow: Increased by over 40% to $454 million.

2. Strategic Updates and Business Highlights

• New Business Wins: Achieved annualized gross new wins of $1.6 billion, a 12% increase from fiscal '24, with a client retention rate of 96.3%.
• Major Contracts: Secured significant contracts including a multi-year agreement with the University of Pennsylvania Health System, the largest contract win in U.S. healthcare.
• International Growth: International segment reported 14% organic revenue growth, with successful new client acquisitions across various sectors.
• Supply Chain Expansion: Added over $1 billion in new purchasing spend for the second consecutive year, enhancing technology capabilities in supply chain operations.

3. Forward Guidance and Outlook

• Fiscal '26 Expectations:
  • Organic Revenue: Projected between $19.45 billion and $19.85 billion (7% to 9% growth).
  • AOI: Expected between $1.1 billion and $1.15 billion (12% to 17% growth).
  • Adjusted EPS: Anticipated in the range of $2.18 to $2.28 (20% to 25% growth).
  • Leverage Ratio: Expected to drop below 3x.

4. Bad News, Challenges, or Points of Concern

• Timing of New Account Openings: Some new business openings were deferred, impacting Q4 revenue; however, this was deemed appropriate for effective transitions.
• Increased Costs: Higher incentive-based compensation and medical claims impacted earnings; the company is taking steps to manage these costs moving forward.
• Market Conditions: Inflation is expected to remain around 3%, and the company is closely monitoring macroeconomic factors that could impact operations.

5. Notable Q&A Insights

• Client-Driven Delays: Delays in new account openings were primarily due to client needs rather than Aramark's operational issues, with significant impacts noted in sectors like Corrections and Healthcare.
• Pipeline Strength: The new business pipeline remains robust, with expectations for strong performance in fiscal '26, including significant new contracts.
• Retention Rates: Management expressed confidence in maintaining high retention rates, aiming for 95% as a baseline, with aspirations to exceed this in the future.
• Margin Outlook: While there may be initial costs associated with new contracts, management believes these will be offset by operational efficiencies and productivity gains.

Overall, Aramark's Q4 2025 results reflect strong growth and operational performance, with a positive outlook for fiscal '26 despite some challenges related to timing and cost management.